Sign in Subscribe
Securities law

Securities Class Action Filed Against Hims & Hers Health, Inc.

Strategic Insights

— 1 min read

Investors who suffered losses in Hims & Hers Health, Inc. (HIMS) between April 29, 2025, and June 22, 2025, may be eligible to join a federal securities class action. The lawsuit alleges that the company and its executives made false and misleading statements about its business, operations, and prospects. The court-appointed lead plaintiff is seeking to recover damages on behalf of affected investors.

Key Takeaways:

  • A federal securities class action has been filed against Hims & Hers Health, Inc. (HIMS) alleging false and misleading statements about the company's business, operations, and prospects.
  • The lawsuit claims that Hims was engaged in the "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy(R) that put patient safety at risk."
  • Novo Nordisk announced the termination of its partnership with Hims on June 23, 2025, stating that Hims "has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk."
  • Hims' stock price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025, following the announcement of the partnership termination.
  • The court-appointed lead plaintiff is an investor with the largest financial interest in the relief sought by the class.
  • Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice.
  • Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. and encourages investors to contact them directly to discuss their options.

Statistics:

  • Hims' stock price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025.
  • The partnership between Hims and Novo Nordisk was terminated on June 23, 2025.
  • The court-appointed lead plaintiff has the largest financial interest in the relief sought by the class.

Sources:

  • Globe Newswire, "Faruqi & Faruqi, LLP Investigates Hims & Hers Health, Inc. (HIMS) following FTC Allegations of Deceptive Marketing practices put patient safety at risk" (August 05, 2025)
  • Faruqi & Faruqi, LLP website (www.faruqilaw.com)
  • Novo Nordisk press release, "Novo Nordisk Ends Partnership with Hims & Hers Health, Inc." (June 23, 2025)

Read more